[Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
Zhonghua Nan Ke Xue
; 16(6): 547-51, 2010 Jun.
Article
em Zh
| MEDLINE
| ID: mdl-20608362
ABSTRACT
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Glutamato Carboxipeptidase II
/
Antígenos de Superfície
Limite:
Humans
/
Male
Idioma:
Zh
Revista:
Zhonghua Nan Ke Xue
Assunto da revista:
MEDICINA REPRODUTIVA
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
China